Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Siu, LL
  • Hotte, Sebastien
  • Laurie, SA
  • Singh, S
  • Winquist, E
  • Chia, SKL
  • Chen, EX
  • Chan, KK
  • Wang, T
  • Taylor, I
  • Ruiz-Garcia, A
  • Mormont, C
  • Soulieres, D

publication date

  • May 20, 2011